Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer
| Autor: | B. Schüll, Markus Raderer, B. Schneeweiss, F. Lang, G. V. Kornek, D. Depisch, Wolfgang Fiebiger, Werner Scheithauer, A. Lenauer, Claudia Gedlicka |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Paclitaxel medicine.medical_treatment cisplatin Adenocarcinoma Neutropenia Gastroenterology Clinical chemistry.chemical_compound Stomach Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine human granulocyte colony-stimulating factor Humans Survival rate Aged Cisplatin Chemotherapy business.industry gastric cancer palliative chemotherapy Combination chemotherapy Middle Aged medicine.disease Hematologic Diseases Surgery Granulocyte colony-stimulating factor Survival Rate Treatment Outcome Oncology chemistry Erythropoietin Female erythropoietin business medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/sj.bjc.6600345 |
| Popis: | A phase II trial was performed to determine the antitumour efficacy and tolerance of combined paclitaxel and cisplatin with or without hematopoetic growth factor support in patients with advanced gastric cancer. Forty-five patients with histologically confirmed metastatic gastric cancer were entered in this trial. Treatment consisted of 2-weekly courses of paclitaxel 160 mg per m2 and cisplatin 60 mg per m2 both given on day 1. Depending on absolute neutrophil counts on the days of scheduled chemotherapeutic drug administration (1000–2000 per μl), a 5-day course of human granulocyte colony-stimulating factor 5 μg kg−1 per day was given subcutaneously; in addition, if haemoglobin was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|